Review article: Biological activity markers in inflammatory bowel disease

Alimentary Pharmacology and Therapeutics

Volumn 25, Issue 3, 2007, Pages 247-255

  Desai, D ^a   Faubion, W A ^b   Sandborn, W J ^b  

^a P D HINDUJA NATIONAL HOSPITAL   (India)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; ALPHA 1 ANTITRYPSIN; ANGIOGENIC PROTEIN; BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALPROTECTIN; CELL ADHESION MOLECULE; CYTOKINE; FIBRINOGEN; INTEGRIN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 8; LACTOFERRIN; LEUKOCYTE ELASTASE; MYELOPEROXIDASE; OROSOMUCOID; SERUM AMYLOID A; TENASCIN; THROMBOPOIETIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; UNINDEXED DRUG;

CLASSIFICATION; DISEASE ACTIVITY; DISEASE ASSOCIATION; ENTERITIS; ERYTHROCYTE SEDIMENTATION RATE; FECES ANALYSIS; HUMAN; INFLAMMATION; PREDICTION; PRIORITY JOURNAL; RELAPSE; REVIEW; SEROLOGY;

BIOLOGICAL MARKERS; HUMANS; INFLAMMATORY BOWEL DISEASES;

EID: 33846312085     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.03184.x     Document Type: Review

References (65)

1. Gabay C, Kushner I. Acute phase reactants and other systemic responses to inflammation. N Engl J Med 1999; 340: 448-54.
2. Dearing WH, McGuckin WH, Elveback LR. Serum alpha1-acid glycoprotein in chronic ulcerative colitis. Gastroenterology 1969; 56: 295-303.
3. Fagan EA, Dyck RF, Maton PN, et al. Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis. Eur J Clin Invest 1982; 12: 351-60.
4. Sachar DB, Smith H, Chan S, Cohen LB, Lichtiger S, Messer J. Erythrocytic sedimentation rate as a measure of clinical activity in inflammatory bowel disease. J Clin Gastroenterol 1986; 8: 647-50.
5. Sachar DB, Luppescu NE, Bodian C, Shlien RD, Fabry TL, Gumaste VV. Erythrocyte sedimentation as a measure of Crohn's disease activity: opposite trends in ileitis versus colitis. J Clin Gastroenterol 1990; 12: 643-6.
6. Andres C, Descos L, Landais P, et al. Assessment of appropriate laboratory measurements to supplement the Crohn's disease activity index. Gut 1981; 22: 571-4.
7. Jensen KB, Jarnum S, Koudahl G, et al. Serum orosomucoid levels in ulcerative colitis. Its relation to clinical activity, protein loss, and turnover of albumin and IgG. Scand J Gastroenterol 1976; 11: 177-93.
8. Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis 2004; 10: 661-5.
9. Solem CA, Loftus EV Jr, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 2005; 11: 707-12.
10. Saverymuttu SH, Hodgson HJ, Chadwick VS, et al. Differing acute phase responses in Crohn's disease and ulcerative colitis. Gut 1986; 27: 809-13.
11. Hammer HB, Kvein TK, Glennas A, et al. A longitudinal study calprotectin as an inflammatory marker in patients with reactive arthritis. Clin Exp Rheumatol 1995; 13: 59-64.
12. Florin TH, Paterson EW, Fowler EV, Radford-Smith GL. Clinically active Crohn's disease in presence of low C-reactive protein. Scand J Gastroenterol 2006; 41: 306-11.
13. Boiliviant M, Leoni M, Tariciotti D, et al. The clinical significance of serum C reactive protein in Crohn's disease: result of a prospective longitudinal study. J Clin Gastroenterol 1988; 10: 401-5.
14. Consigney Y, Modigliani R, Colombel JF, et al. Biologic markers of short-term relapse in Crohn's disease. Gastroenterology 2001; 20 (Suppl.): A53.
15. Wright JP, Young GO, Tigler-Wybrandi N. Predictores of acute relapse of Crohn's disease. A laboratory and clinical study. Dig Dis Sci 1987; 32: 164-70.
16. Talstad I, Rootwelt K, Gjone E. Thrombocytosis in ulcerative colitis and Crohn's disease. Scand J Gastroenterol 1973; 8: 135-8.
17. Philips MS. Dronfield MW. Platelet count in patients with Crohn's disease. Br Med J 1983; 286: 1895.
18. Prior C, Bollbach R, Fuchs D, et al. Urinary neopterin, a marker of clinical activity in patients with Crohn's disease. Clin Chim Acta 1986; 155: 11-21.
19. Niederwieser D, Fuchs D, Hausen A, et al. Neopterin as a new biochemical marker in the clinical assessment of ulcerative colitis. Immunobiology 1985; 170: 320-6.
20. Hyams JS, Treem WR, Eddy E, Wyzga N, Moore RE. Tumor necrosis factor-alpha is not elevated in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1991; 12: 233-6.
21. Murch SH, Lamkin VA, Savage MO, Walker-Smith JA, MacDonald TT. Serum concentration of tumor necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut 1991; 32: 913-7.
22. Gardiner KR, Halliday MI, Barclay GR, et al. Significance of systemic endotoxaemia in inflammatory bowel disease. Gut 1995; 36: 897-901.
23. Braegger CP, Nicholls S, Murch SH, et al. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992; 339: 89-91.
24. Saiki T, Mitsuyama K, Toyonaga A, et al. Detection of pro and anti-inflammatory cytokines in stools of patients with inflammatory bowel disease. Scand J Gastroenterol 1998; 33: 616-22.
25. Stronkhorst A, Jansen J, Tytgat G, et al. Soluble IL-2 and TNF receptors p55 and p75 in Crohn's disease. Gastroenterology 1994; 106: A779.
26. Van Dullemen HM, van Deventer SJ, Hommes DW, et al. Treatment of Creohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995; 105: 129-35.
27. Propst A, Propst T, Herold M, et al. Interleukin-1 receptor antagonist in differential diagnosis of inflammatory bowel disease. Eur J Gastroenterol Hepatol 1995; 7: 1031-6.
28. Casini-Raggi V, Kam L, Chong YJT, et al. Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. J Immunol 1995; 154: 2434-40.
29. Williams AJ, Symons JA, Watchet K, et al. Soluble interleukin-2 receptors and disease activity in Crohn's disease. J Autoimmun 1992; 5: 251-9.
30. Nielsen OH, Brynsskov J. Soluble interleukin-2 receptors in ulcerative colitis. Mediators Inflamm 1993; 2: 115-8.
31. Mahida YR, Kurlac L, Gallaghar A, et al. High circulating concentrations of interleukin-6 in active Crohn's disease but not ulcerative colitis. Gut 1992; 32: 1531-4.
32. Gustot T, Lemmers A, Louis E, et al. Profile of soluble cytokine receptors in Crohn's disease. Gut 2005; 54: 488-95.
33. Jones SC, Evans SW, Lobo AJ, Cesca M, Axon AT, Whicher JT. Serum Interleukin-8 in inflammatory bowel disease. J Gastroenterol Hepatol 1993; 8: 508-12.
34. Kucharzik T, Stoll R, Lugering N, Domschke W. Circulating antiinflammatory cytokine IL-10 in patients with inflammatory bowel disease (IBD). Clin Exp Immunol 1995; 100: 452-6.
35. Kader HA, Tchernev VT, Satyaraj E, et al. Protein microarray analysis of disease activity in pediatric inflammatory bowel disease demonstrates elevated serum PLGF, IL-7, TGF-beta1, and IL-12p40 levels in Crohn's disease and ulcerative colitis patients in remission versus active disease. Am J Gastroenterol 2005; 100: 414-23.
36. Stallmach A, Giese T, Schmidt C, Ludwig B, Mueller-Molaian I, Meuer SC. Cytokine/chemokine transcript profiles reflect mucosal inflammation in Crohn's disease. Int J Colorectal Dis 2004; 19: 308-15.
37. Schmidt C, Giese T, Ludwig B, et al. A expression of interleukin-12-related cytokine transcripts in inflammatory bowel disease: elevated interleukin-23p19 and interleukin-27p28 in Crohn's disease but not in ulcerative colitis. Inflamm Bowel Dis 2005; 11: 16-23.
38. Tsukada Y, Nakamura T, Iimura M, Iizuka BE, Hayashi N. Cytokine profile in colonic mucosa of ulcerative colitis correlates with disease activity and response to granulocytapheresis. Am J Gastroenterol 2002; 97: 2820-8.
39. Silva MA, Menezes J, Deslandres C, Seidman EG. Anti-inflammatory role of interleukin-15 in Crohn's disease. Inflamm Bowel Dis 2005; 11: 219-30.
40. Goggins MG, Goh J, O'Connell MA, Weir DG, Kelleher D, Mahmud N. Soluble adhesion molecules in inflammatory bowel disease. Ir J Med Sci 2001; 170: 107-11.
41. Assche GV, Rutgeerts P. Physiological basis for novel drug therapies used to treat the inflammatory bowel disease: I. Immunology and therapeutic potential of antiadhesion molecule therapy in inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 2005; 288: 169-74.
42. Magro F, Araujo F, Pereira P, Meireles E, Diniz-Ribeiro M, Velosom FT. Soluble selectins, sICAM, sVCAM, and angiogenic proteins in different activity groups of patients with inflammatory bowel disease. Dig Dis Sci 2004; 49: 1265-74.
43. Riedl S, Tandara A, Reinshagen M, et al. Serum tenascin-C is an indicator of inflammatory bowel disease activity. Int J Colorectal Dis 2001; 16: 285-91.
44. Zissis M, Afroudakis A, Galanopoulos G, et al. B2 microglobulin: is it a reliable marker of activity in inflammatory bowel disease? Am J Gastroenterol 2001; 96: 2177-83.
45. Gouni-Berthold I, Baumeister B, Wegel E, Berthold HK, Vetter H, Schmidt C. Neutrophil-elastase in chronic inflammatory bowel disease: a marker of disease activity? Hepatogastroenterology 1999; 46: 2315-20.
46. Tibble JA, Bjarnason I. Non-invasive investigations of inflammatory bowel disease. World J Gastroenterol 2001; 7: 460-5.
47. Fagerhol MK, Dale I, Anderson I. Release and quantification of leukocyte derived protein (L1). Scand J Haematol 1980; 24: 393-8.
48. Roseth AG, Schmidt TN, Fagerhol MK. Correlation between fecal excretion of indium 111-labeled granulocytes and calprotectin, a granulocyte marker protein in patients with inflammatory bowel disease. Scand J Gastroenterol 1999; 34: 50-4.
49. Tibble JA, Teahan K, Thjodleifssan B, et al. A simple method for assessing intestinal inflammation in Crohn's disease. Gut 2000; 47: 506-13.
50. Roseth AG, Aadland E, Jahnsen J, et al. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion 1997; 58: 176-80.
51. Roseth AG, Fagerhol MK, Aadland E, Schjonsby H. Assessment of neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol 1992; 27: 793-8.
52. Taehon K, Roseth AG, Foster R, Bjarnason I. Fecal calprotectin: a simple sensitive quantitative measure of intestinal inflammation in man (abstract). Gastroenterology 1997; 112 (Suppl.): A1103.
53. Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterolgy 2000; 119: 15-22.
54. Costa F, Mumolo MG, Ceccarelli L, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than I Crohn's disease. Gut 2005; 54: 364-8.
55. Kane SV, Sandborn WJ, Rufo PA, et al. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol 2003; 98: 1309-14.
56. von der Sluys Veer A, Biemond I, Verspaget HW, et al. Fecal parameters in the assessment of activity in inflammatory bowel disease. Scand J Gastroenterol Suppl 1999; 230: 106-10.
57. Walker TR, Land ML, Cook TM, et al. Serial fecal lactoferrin measurements are useful in the interval assessment of patients with active and inactive inflammatory bowel disease. Gastroenterology 2004; 126: A215.
58. D'Inca R, Dal Pont E, Di Lee V, et al. Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int J Colorectal Dis 2006; July 13. (Epub).
59. Langhorst J, Elsenbruch S, Mueller T, et al. Comparison of 4 neutrophil-derived proteins in feces as indicators of disease activity in ulcerative colitis. Inflamm Bowel Dis 2005; 11: 1085-91.
60. O'Mahony S, Choudari CP, Barton JR, Walker S, Ferguson A. Gut lavage fluid proteins as markers of activity of inflammatory bowel disease. Scand J Gastroenterol 1991; 26: 940-4.
61. Brignola C, Campieri M, Bazzocchi G, Farruggia G, Tragnone A, Lanfranchi GA. A laboratory index for predicting relapse in asymptomatic patients with Crohn's disease. Gastroenterology 1986; 91: 1490-4.
62. Reinisch W, Gasche C, Tillinger W, et al. Clinical relevance of serum interleukin-6 in Crohn's disease: single point measurements, therapy monitoring, and prediction of clinical relapse. Am J Gastroenterol 1999; 94: 2156-64.
63. Louis E, Belaiche J, Van Kemseke C, Schaaf N, Mahieu P, Mary JY. Soluble interleukin-2 receptor in Crohn's disease. Assessment of disease activity and prediction of relapse. Dig Dis Sci 1995; 40: 1750-6.
64. Bitton A, Peppercorn MA, Antonioli DA, et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology 2001; 120: 13-20.
65. Yamamoto T, Umegae S, Kitagawa T, Matsumoto K. Systemic and local cytokine production in quiescent ulcerative colitis and its relationship to future relapse: a prospective pilot study. Inflamm Bowel Dis 2005; 11: 589-96.